by Lisa Nadal | Feb 21, 2024 | 2024, Press Releases
More detailsby Lisa Nadal | Feb 20, 2024 | 2024, Press Releases
FIBROSARC (NCT04650984) is a Phase III trial evaluating Onfekafusp alfa (L19TNF, also known as Fibromun) plus doxorubicin versus doxorubicin alone as front-line therapy for patients with advanced or metastatic Soft Tissue Sarcoma An Independent Data and Safety...by Lisa Nadal | Dec 4, 2023 | 2023
See more detailsby Lisa Nadal | Dec 4, 2023 | 2023
See more detailsby Lisa Nadal | Jul 4, 2023 | Press Releases
The study was conducted by scientists at Philochem AG, the wholly owned Swiss subsidiary company of the Philogen group. The paper can be accessed on the Nature Chemistry website at the following link. Nat_chem_280223_press_release
Recent Comments